There were 53 FDA approved drugs in 2020.
These range from the ever-menacing COVID-19 to more obscure and rare diseases – such as Hutchinson-Gilford progeria syndrome; a condition characterized by the rapid onset of the appearance of aging in childhood.
Below we have put together the complete list of FDA drug approvals in 2020. Take some time to learn more about each drug and the condition with which it is now licensed to treat. As new medicines, there is still a lot to learn – particularly when it comes to adverse effects and drug interactions. Aspects of individual mechanisms may also be as-yet uncertain. And that is normal; it is part of the long and arduous – but nevertheless rewarding – process of drug development.
Unlike many others who failed to receive approval, these 53 medicines have come through a complex regimen of tests and regulatory barriers – demonstrating their clinical efficacy, pharmacology, and utility; as well as value in the treatment of both common and rare diseases. Many of these drugs may also become the first of what will become an established drug class.
So, with these factors in mind, let’s now take a few minutes to review all fifty-three of the FDA approved drugs in 2020.
Medicine | Active Ingredient | Indication(s) |
Gemtesa | vibegron | Overactive bladder |
Ebanga | ansuvimab-zykl | Ebola |
Orgovyx | relugolix | Advanced prostate cancer |
Margenza | margetuximab (anti-HER2 mAb | HER2+ breast cancer |
Klisyri | tirbanibulin | Actinic Keratosis (face or scalp) |
Orladeyo | berotralstat | Hereditary angioedema |
Gallium 68 PSMA-11 | Gallium 68 PSMA-11 | Prostate cancer detection / localization |
Danyelza | naxitamab-gqgk | Refractory or relapsed neuroblastoma |
Imcivree | setmelanotide | Obesity; and control of hunger in patients with pro-opiomelanocortin deficiency |
Oxlumo | lumasiran | Hyperoxaluria type 1 |
Zokinvy | lonafarnib | Hutchinson-Gilford progeria syndrome |
Veklury | remdesivir | COVID-19 |
Inmazeb | atoltivimab, maftivimab, and odesivimab-ebgn | Ebola virus |
Gavreto | pralsetinib | Non-small lung cancer |
Detectnet | copper Cu 64 dotatate injection | Detection of certain kinds of neuroendocrine tumor |
Sogroya | somapacitan-beco | Replacement of endogenous growth hormone |
Winlevi | clascoterone | Acne |
Enspryng | satralizumab-mwge | Neuromyelitis optica spectrum disorder |
Viltepso | viltolarsen | Duchenne muscular dystrophy |
Olinvyk | oliceridine | Acute pain in certain adults |
Evrysdi | risdiplam | Spinal muscular atrophy |
Lampit | nifurtimox | Chagas disease in patients < 18 years |
Blenrep | belantamab mafodotin-blmf | Multiple myeloma |
Monjuvi | tafasitamab-cxix | Relapsed or refractory diffuse large B-cell lymphoma |
Xeglyze | abametapir | Head lice |
Inqovi | decitabine and cedazuridine | Myelodysplastic syndromes |
Rukobia | fostemsavir | HIV |
Byfavo | remimazolam | For sedation |
Dojolvi | triheptanoin | Treatment of long-chain fatty acid oxidation disorders |
Zepzelca | lurbinectedin | Metastatic small cell lung cancer |
Uplizna | inebilizumab-cdon | Neuromyelitis optica spectrum disorder |
Tauvid | flortaucipir F18 | Alzheimer’s disease diagnostic agent |
Artesunate | artesunate | Severe forms of malaria |
Cerianna | fluoroestrdiol F18 | Diagnostic imaging agent for breast cancer |
Qinlock | ripretinib | Advanced GISTs |
Retevmo | selpercatinib | Certain kinds of lung and thyroid cancers |
Tabrecta | capmatinib | Non-small cell lung cancer |
Ongentys | opicapone | Parkinson’s disease during “off” periods |
Trodelvy | sacituzumab govitecan-hziy | Metastatic triple-negative breast cancer |
Pemazyre | pemigatinib | Cholangiocarcinoma |
Tukysa | tucatinib | Advanced unresectable or metastatic HER2-positive breast cancer |
Koselugo | selumetinib | Neurofibromatosis type 1 |
Zeposia | ozanimod | Relapsing forms of multiple sclerosis |
Isturisa | osilodrostat | Cushing’s disease |
Sarclisa | isatuximab | Multiple myeloma |
Nurtec ODT | rimegepant | Migraine |
Barhemsys | amisulpride | Prevention of post-operative nausea and vomiting |
Vyepti | eptinezumab-jjmr | Migraine prophylaxis |
Nexletol | bempedoic acid | Heterozygous familial hypercholesterolemia |
Pizensy | lactitol | Chronic idiopathic constipation (CIC) |
Tazverik | tazemetostat | Epithelioid sarcoma |
Tepezza | teprotumumab-trbw | Thyroid eye disease |
Ayvakit | avapritinib | Unresectable or metastatic GIST |